Final results of DIADEM, a phase II study to investigate the efficacy and safety of durvalumab in advanced pretreated malignant pleural mesothelioma
暂无分享,去创建一个
G. Ceresoli | M. Mencoboni | F. Grosso | A. Ardizzoni | M. D’Incalci | D. Poli | P. Zucali | F. De Vincenzo | M. Perrino | S. Frega | G. Pasello | F. Galli | F. Pagni | D. Cortinovis | S. Canova | A. D’Aveni | M. Bonomi | D. Cortinovis | F. Gelsomino | A. Santoro | F. Bono | F. Colonese | V. Torri | I. De Simone | L. Carlucci | L. Sala | M. Belletti | E. Rulli | M. Abbate | A. D. De Angelis | F. Ugo | E. Sala | D. S. F. M.I. L. E. M. F. F. G.L. A. M. F. A. F. M. P Cortinovis Canova Colonese Abbate Sala Sala Pe | M. Perez Gila | A. D. de Angelis
[1] A. Addeo,et al. Systemic therapy for pre-treated malignant mesothelioma: A systematic review, meta-analysis and network meta-analysis of randomised controlled trials. , 2022, European journal of cancer.
[2] A. Mansfield,et al. The Predictive and Prognostic Nature of Programmed Death-Ligand 1 in Malignant Pleural Mesothelioma: A Systematic Literature Review , 2022, JTO clinical and research reports.
[3] G. Scagliotti,et al. A systematic review and meta-analysis of trials assessing PD-1/PD-L1 immune checkpoint inhibitors activity in pre-treated advanced stage malignant mesothelioma. , 2022, Critical reviews in oncology/hematology.
[4] V. Velculescu,et al. Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survival, genomic and immunologic analyses from the phase 2 PrE0505 trial , 2021, Nature Medicine.
[5] C. Richards,et al. Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial , 2021, The Lancet. Oncology.
[6] A. Jackson,et al. Management of Advanced Pleural Mesothelioma-At the Crossroads. , 2021, JCO Oncology Practice.
[7] C. Pritchard,et al. Matter of TIME: the tumor-immune microenvironment of mesothelioma and implications for checkpoint blockade efficacy , 2021, Journal for ImmunoTherapy of Cancer.
[8] A. Mansfield,et al. LBA65 First-line nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) in patients (pts) with unresectable malignant pleural mesothelioma (MPM): 3-year update from CheckMate 743 , 2021, Annals of Oncology.
[9] S. Popat,et al. Immune Checkpoint Inhibition for Unresectable Malignant Pleural Mesothelioma , 2021, Drugs.
[10] G. Ceresoli,et al. Immune checkpoint inhibitors in mesothelioma: a turning point , 2021, The Lancet.
[11] A. Mansfield,et al. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial , 2021, The Lancet.
[12] M. Stockler,et al. Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in. , 2020, The Lancet. Oncology.
[13] U. Dafni,et al. A multicentre randomised phase III trial comparing pembrolizumab vs single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial. , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.
[14] M. Okada,et al. Clinical Efficacy and Safety of Nivolumab: Results of a Multicenter, Open-label, Single-arm, Japanese Phase II study in Malignant Pleural Mesothelioma (MERIT) , 2019, Clinical Cancer Research.
[15] J. Nemunaitis,et al. Efficacy and Safety of Avelumab Treatment in Patients With Advanced Unresectable Mesothelioma: Phase 1b Results From the JAVELIN Solid Tumor Trial , 2019, JAMA oncology.
[16] S. Lantuejoul,et al. Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial. , 2019, The Lancet Oncology.
[17] D. Planchard,et al. Hyperprogressive Disease in Patients With Advanced Non–Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy , 2018, JAMA oncology.
[18] E. Thunnissen,et al. Programmed Death 1 Blockade With Nivolumab in Patients With Recurrent Malignant Pleural Mesothelioma , 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[19] A. D’Incecco,et al. Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): an open-label, non-randomised, phase 2 study. , 2018, The Lancet. Respiratory medicine.
[20] K. Nackaerts,et al. Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial. , 2017, The Lancet. Oncology.
[21] A. Santoro,et al. Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial. , 2017, The Lancet. Oncology.
[22] Charles Ferté,et al. Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1 , 2016, Clinical Cancer Research.
[23] B. Milleron,et al. Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial , 2016, The Lancet.
[24] K. Nackaerts,et al. Second-line (post-study) chemotherapy received by patients treated in the phase III trial of pemetrexed plus cisplatin versus cisplatin alone in malignant pleural mesothelioma. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.
[25] M. Byrne,et al. Modified RECIST criteria for assessment of response in malignant pleural mesothelioma. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.
[26] Claude Denham,et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.